The earnings call highlighted a strong financial performance in 2024 with significant revenue and profitability growth. Strategic investments in biotechnology and operational improvements were emphasized as key drivers of success. However, challenges in the functional ingredients segment and adverse forex impacts were noted. Overall, the positive achievements in revenue growth and debt reduction outweighed the negatives.

Company Guidance

During the International Flavors & Fragrances Inc. (IFF) earnings call for the fourth quarter and full year 2024, the company provided guidance for 2025, anticipating sales to range between $10.6 billion to $10.9 billion, reflecting comparable currency-neutral growth of 1% to 4%. Adjusted operating EBITDA for 2025 is expected to be between $2 billion to $2.15 billion, indicating 5% to 10% growth on a comparable currency-neutral basis. The company plans to increase investments in research and development, commercial capabilities, and capital expenditures, targeting approximately 6% of sales in CapEx, split between maintenance, deferred investment catch-up, growth investments, and digital transformation initiatives. IFF is also looking to complete the divestiture of Pharma Solutions by mid-2025, which is anticipated to have adverse impacts of approximately 5 percentage points on sales growth and 6 percentage points on adjusted EBITDA growth. The outlook includes assumptions about the operating environment normalizing relative to 2024, with expected modest pricing contributions and impacts from foreign exchange rates, particularly the euro, Brazilian real, and Argentine peso.

Revenue Growth

International Flavors & Fragrances Inc. delivered $11.5 billion in sales for 2024, representing a 6% comparable currency-neutral growth.

Profitability Improvement

The company reported over $2.2 billion in adjusted operating EBITDA for 2024, representing 16% comparable growth.

Debt Reduction

Net debt to credit-adjusted EBITDA improved to 3.8 times at the end of 2024 from 4.5 times at the end of 2023.

Segment Performance

Nourish segment sales increased by 4% year over year, Health and Biosciences 6%, Scent 7%, and Pharma Solutions 12% on a comparable currency-neutral basis.

Strategic Investments

Increased emphasis on biotechnology and investments in R&D, commercial capabilities, and CapEx for high-growth, high-margin businesses.

---

International Flavors & Fragrances (IFF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IFF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 12, 2025	2025 (Q1)	1.14 / -	1.13	―	―	―
Feb 18, 2025	2024 (Q4)	0.81 / 0.97	0.72	34.72% (+0.25)
Nov 05, 2024	2024 (Q3)	1.07 / 1.04	0.89	16.85% (+0.15)
Aug 06, 2024	2024 (Q2)	0.99 / 1.16	0.86	34.88% (+0.30)
May 06, 2024	2024 (Q1)	0.86 / 1.13	0.87	29.89% (+0.26)
Feb 20, 2024	2023 (Q4)	0.76 / 0.72	0.97	-25.77% (-0.25)
Nov 06, 2023	2023 (Q3)	0.75 / 0.89	1.36	-34.56% (-0.47)
Aug 07, 2023	2023 (Q2)	1.10 / 0.86	1.54	-44.16% (-0.68)
May 08, 2023	2023 (Q1)	0.89 / 0.87	1.69	-48.52% (-0.82)
Feb 08, 2023	2022 (Q4)	0.96 / 0.97	1.1	-11.82% (-0.13)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

IFF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 18, 2025	$86.45	$81.99	-5.16%
Nov 05, 2024	$98.64	$87.16	-11.64%
Aug 06, 2024	$95.66	$93.41	-2.35%
May 06, 2024	$87.54	$93.14	+6.40%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---